AGIOS PHARMACEUTICALS, INC. - 10-Q Filing

Agios Pharmaceuticals reports Q3 2026 financial results including detailed breakdown of Vorasidenib royalty rights and segment performance.

SEC EDGAR ·

Tickers: $AGIO

Read the full article at SEC EDGAR

More Regulatory news